Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for the year ended December 31, 2025, and provide a business update on March 30, 2026. The Company will hold live conference calls in English and Mandarin on March 30, 2026, Beijing Time.

The English session of the conference call will be held at 9:00 AM on March 30, 2026, Beijing Time (9:00 PM U.S. Eastern Time on March 29, 2026), and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (10:30 PM U.S. Eastern Time on March 29, 2026).

The conference calls can be accessed by the following links:

For English Session:

Time: 9:00 AM Beijing Time, Monday, March 30, 2026
(9:00 PM U.S. Eastern Time, Sunday, March 29, 2026)

Register and Webcast Link:

https://insilico.zoom.us/w/81195639919?pwd=i153PUfkONs5INk8mgvLmmttveLqc0.1

Participants are required to pre-register for the English conference call using the link above. After registration is approved, participants will receive the webinar access link and dial-in information via email.

For Mandarin Session:

Time: 10:30 AM Beijing Time, Monday, March 30, 2026
(10:30 PM U.S. Eastern Time, Sunday, March 29, 2026)

Register and Webcast Link:
https://research.citics.com/tel/info/1_2047925

Participants are required to pre-register for the Mandarin conference call using the link above.

Alternatively, participants may dial in to the conference call using below dial-in information:

The replay of English session will be available shortly after the call and can be accessed by visiting the Company's website at https://insilico.com/.

View original content:https://www.prnewswire.com/news-releases/insilico-medicine-to-announce-2025-financial-results-on-march-30-2026-302713432.html

SOURCE Insilico Medicine